Last reviewed · How we verify
Echocardiography — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Perfluoropropane | Perfluoropropane | National Eye Institute (NEI) | ||||
| Octafluoropropane | Octafluoropropane | University of Alabama at Birmingham |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- National Eye Institute (NEI) · 1 drug in Echocardiography
- University of Alabama at Birmingham · 1 drug in Echocardiography
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Echocardiography:
- Echocardiography treatment updates — RSS
- Echocardiography treatment updates — Atom
- Echocardiography treatment updates — JSON
Cite this brief
Drug Landscape (2026). Echocardiography — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/echocardiography. Accessed 2026-06-10.
Related
- Echocardiography full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing